Similarly, the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) do not advise serial measurements for CEA/CA 19-9 during the medical assessment of early CRC due to the lack of data indicating that it increases survival benefit [23]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.